Immune Checkpoint Inhibitors

Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease

Immunotherapy Tolerable for Cancer Patients With Rheumatologic Disease

By

In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

By

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic Disorders

Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic Disorders

By

A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs